# South Korea Influenza Diagnostics Market

> South Korea Influenza Diagnostics Market Research Report: Size, Share, Trend Analysis By Types (PCR Tests, Antigen Tests, Serology Tests, Viral Culture, Rapid Diagnostic Tests), By Product (Reagents, Kits, Instruments, Consumables), By End-user (Hospitals, Clinics, Laboratories, Home Care), and By Technique (Molecular Diagnostics, Immunodiagnostics, Cell Culture) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.29%
- **2024:** $ 185.28 Million
- **2025:** $ 200.64 Million
- **2035:** $ 444.87 Million
- **Key Players:** Roche (CH), Abbott (US), Thermo Fisher Scientific (US), Siemens Healthineers (DE), BD (US), Cepheid (US), QuidelOrtho (US), Hologic (US)

**Report ID:** MRFR/MED/55099-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-influenza-diagnostics-market-56865

---

## Market Summary

## **South Korea Influenza Diagnostics Market Overview**

**As per MRFR analysis, the South Korea Influenza Diagnostics Market Size was estimated at 171.5 (USD Million) in 2023.The South Korea Influenza Diagnostics Market is expected to grow from 178.5(USD Million) in 2024 to 445 (USD Million) by 2035. The South Korea Influenza Diagnostics Market CAGR (growth rate) is expected to be around 8.659% during the forecast period (2025 - 2035).**

### **Key South Korea Influenza Diagnostics Market Trends Highlighted**

The market for influenza diagnostics in South Korea is undergoing a dramatic change as a result of the government's initiatives to improve healthcare capabilities and the public's increased awareness of respiratory illnesses. Rapid and precise diagnostic methods are in high demand due to the rise in viral infection rates.

The healthcare system in South Korea is investing in cutting-edge technology, such as point-of-care testing and molecular diagnostics, to increase the accessibility and dependability of testing. Government programs focused at enhancing public health infrastructure support the focus on early detection to stop the spread of influenza.

The creation of novel products that target certain virus strains and the uptake of telehealth services present opportunities in the South Korean influenza diagnostics industry. Businesses should look into partnering with healthcare providers to offer integrated services that expedite the testing process as more people look for speedy testing options.

More specialized diagnostic options are also made possible by the growing trend of personalized medicine. Digital health solutions have grown significantly in recent years, with telemedicine becoming more and more well-liked, particularly in the wake of the pandemic. Digital healthcare platforms are being promoted by the government and can be used to provide remote diagnostic services.

The need for efficient diagnostic methods to track epidemics is also fueled by the South Korean health authorities' push for vaccination campaigns, particularly during the busiest influenza seasons. All things considered, South Korea's influenza diagnostics industry is changing with an emphasis on technology breakthroughs, expanding access to healthcare, and a proactive approach to illness control.

**Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review**

## **South Korea Influenza Diagnostics Market Drivers**

### **Rising Incidence of Influenza Cases in South Korea**

The South Korea Influenza Diagnostics Market is experiencing significant growth due to the rising incidence of influenza cases. According to the Korea Centers for Disease Control and Prevention (KCDC), the rate of influenza infections has shown an alarming increase, with reported cases rising by approximately 20% in the past three years.

This growing prevalence of influenza places a heightened demand on diagnostic solutions, as accurate and timely detection is crucial for effective disease management. Furthermore, during seasonal outbreaks, healthcare providers emphasize the importance of[rapid diagnostic](../../../reports/rapid-diagnostic-kit-market-43472) tests to quickly identify infected individuals and initiate treatment.

The increasing burden of influenza on the healthcare system is driving innovations in diagnostic technologies, with companies such as Seegene and Hologic introducing advanced molecular diagnostic assays tailored to the specific needs of South Korea's healthcare sector.

The increasing awareness among the population regarding early detection will also contribute to the overall demand in the South Korea Influenza Diagnostics Market over the next decade.

### **Government Initiatives in Influenza Prevention**

Government initiatives focused on influenza prevention and control are significant drivers in the South Korea Influenza Diagnostics Market. South Korea's Ministry of Health and Welfare has implemented various vaccination programs aimed at reducing the incidence of influenza.

According to the ministry, approximately 60% of the elderly population received influenza vaccinations in the last season, highlighting the government's commitment to enhancing public health. These initiatives go hand-in-hand with the promotion of early diagnostic testing, leading to a greater requirement for influenza diagnostic tools.

Public health campaigns aimed at educating citizens about the importance of rapid diagnosis are paving the way for increased adoption of diagnostic technologies.

As government funding continues to support research and development in this area, organizations like the Korean Society of Infectious Diseases are actively collaborating with diagnostics firms to enhance testing capabilities and improve public health outcomes in South Korea.

### **Technological Advancements in Diagnostic Methods**

Technological advancements in diagnostic methods are playing a pivotal role in advancing the South Korea Influenza Diagnostics Market. Recent developments in real-time polymerase chain reaction (RT-PCR) and rapid antigen tests enable quicker and more accurate results, catering to the urgent need for efficient diagnosis.

A report from the Korean Institute of Medical Science indicated that RT-PCR tests have a sensitivity of over 90% for detecting influenza, dramatically improving diagnosis compared to traditional methods.

Companies like LG Chem and Samsung Medison are investing heavily in Research and Development to launch cutting-edge diagnostic solutions that meet the clinical needs of healthcare providers. This focus on innovation not only supports the current healthcare landscape but also positions South Korea as a leader in influenza diagnostics within the South Korean and global markets.

## **South Korea Influenza Diagnostics Market Segment Insights**

### **Influenza Diagnostics Market Type Insights**

The South Korea Influenza Diagnostics Market is characterized by a diverse range of types, each serving a specific purpose in the early detection and management of influenza viruses. Among these, PCR Tests stand out due to their high sensitivity and specificity, making them a preferred choice for accurate diagnosis in clinical settings.

They allow for quick turnaround times and help in identifying infection even during the early stages. Meanwhile, Antigen Tests offer significant advantages in terms of speed, as they can deliver results within minutes, thus playing a crucial role in rapid clinical decision-making and outbreak responses. This type of testing is particularly valuable in emergency settings where timely information is critical.

Serology Tests, on the other hand, focus on detecting antibodies in the blood, providing insights into previous infections and immunity levels within the population. This type is particularly helpful for epidemiological studies, enabling health authorities to gauge the spread of the virus over time.

Viral Culture remains a gold standard in the diagnostics space, allowing for the isolation and identification of the influenza virus, which is important for research and vaccine development. This method, although time-consuming, provides comprehensive information about the viral strain, contributing to ongoing surveillance efforts.

Rapid Diagnostic Tests are designed for ease of use and convenience, making them ideal for point-of-care testing. Their ability to deliver results swiftly exacerbates their popularity in various healthcare settings, including rural and remote areas where laboratory facilities may be limited.

The South Korea Influenza Diagnostics Market is experiencing significant interest in these various types, driven by the increasing prevalence of influenza outbreaks and heightened awareness around infectious diseases.

As influenza continues to pose a public health challenge, enhanced testing strategies are becoming increasingly important. The emphasis on quick diagnosis helps manage outbreaks effectively and informs treatment strategies, thereby underlining the crucial role that these different types of diagnostics play in public health management strategies within South Korea.

**Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review**

### **Influenza Diagnostics Market Product Insights**

The South Korea Influenza Diagnostics Market primarily revolves around the Product segment, comprising various components like Reagents, Kits, Instruments, and Consumables. This market is experiencing growth due to the increasing incidence of influenza and the rising need for quick and accurate diagnostic solutions.

Reagents are vital as they play a crucial role in the reliability of tests, facilitating accurate virus identification. Kits, on the other hand, offer convenience and speed, enabling healthcare providers to conduct tests efficiently in both clinical and home settings.

Instruments used for diagnostics are significant as they ensure consistent performance and support advanced testing capabilities, addressing the growing demand for innovative diagnostic tools. Consumables are equally essential as they are used in conjunction with instruments, contributing to the overall effectiveness of testing processes.

The South Korea government has been focusing on enhancing healthcare accessibility, thus promoting investment in influenza diagnostics, which aligns with global health aims to prevent and manage outbreaks effectively.

With a supportive infrastructure and increasing awareness about influenza, market growth in these product categories is poised to continue steadily. The focus on innovation, rapid testing, and reliable results emphasizes the importance of these products within the South Korea Influenza Diagnostics Market, responding to both regional healthcare needs and global trends.

### **Influenza Diagnostics Market****End-use****r Insights**

The End-user segment of the South Korea Influenza Diagnostics Market plays a crucial role in the effective detection and management of influenza, which has become increasingly important in light of recent public health crises. Hospitals are significant players, equipped with advanced diagnostic tools that contribute to rapid patient care and management of influenza outbreaks.

Clinics also serve as vital points of care, often being the first avenue for patients presenting with flu-like symptoms, thereby driving early diagnosis. In the realm of Laboratories, the focus is on precision diagnostics, offering comprehensive testing processes that aid both healthcare providers and public health authorities in tracking influenza trends.

Home Care is an emerging segment, allowing patients to undergo testing in the comfort of their homes, which has gained popularity amid growing demand for convenient healthcare solutions.

With growing awareness about influenza and the importance of timely diagnostics, the demand across all these areas is expected to rise, fueled by technological advancements and healthcare policies aimed at enhancing disease control and prevention in South Korea.

### **Influenza Diagnostics Market Technique Insights**

The South Korea Influenza Diagnostics Market, particularly in the Technique segment, plays a crucial role in enhancing disease detection and management. Among the key methodologies, Molecular Diagnostics has gained prominence due to its ability to provide rapid and accurate results, significantly aiding in early influenza detection, which is pivotal for effective public health response.

Immunodiagnostics, on the other hand, remains significant for its user-friendly applications and quick turnaround times, making it a preferred choice in many clinical settings. Moreover, Cell Culture techniques are crucial in research and development as they enable the isolation and study of different influenza strains, facilitating vaccine development and epidemiological studies.

The growing prevalence of respiratory viruses in South Korea enhances the demand across these methodologies, influenced by governmental health initiatives aimed at improving epidemiological surveillance. Collectively, these techniques exhibit a trend towards integration with advanced technology, thus driving innovation in the South Korea Influenza Diagnostics Market.

## **South Korea Influenza Diagnostics Market Key Players and Competitive Insights**

The competitive insights of the South Korea Influenza Diagnostics Market highlight a dynamic landscape driven by the increasing demand for rapid and accurate influenza diagnostic solutions. The market has experienced significant growth due to heightened awareness around infectious diseases, particularly in light of recent pandemics.

This heightened awareness has pushed healthcare providers and institutions to invest in advanced diagnostic technologies. Key players in this space are actively working towards innovations in test accuracy, speed, and point-of-care diagnostics, which are essential for effective disease management and prevention strategies.

Furthermore, robust research and development initiatives combined with strategic partnerships are central to maintaining a competitive edge in this evolving market. The South Korean government’s focus on enhancing healthcare infrastructure and disease surveillance has also created favorable conditions for market players.

In the context of the South Korea Influenza Diagnostics Market, bioMérieux has established a strong presence through its commitment to delivering high-quality diagnostic solutions. The company is recognized for its innovative approaches to infectious disease testing, underscored by a robust portfolio of molecular diagnostic products tailored to detect influenza viruses accurately.

bioMérieux’s strength lies in its extensive experience in microbiology and infectious diseases, allowing it to develop cutting-edge technologies that meet the needs of healthcare professionals in South Korea.

The collaboration with local health authorities and hospitals enhances their visibility in the market, while continuous investment in research and development secures their position as a preferred choice for influenza diagnostics among healthcare providers.

Bioneer has also made significant strides in the South Korea Influenza Diagnostics Market by leveraging its expertise in molecular biology and biotechnology. The company offers a range of key products and services, including real-time PCR diagnostic kits specifically designed for influenza virus detection.

Bioneer's strengths lie in its agile development capabilities and comprehensive product offerings that cater to the local healthcare needs. Furthermore, the company has been proactive in pursuing strategic partnerships and collaborations, which augment its market reach and enhance its research capacity.

Recent mergers and acquisitions have allowed Bioneer to fortify its technological prowess and expand its product range, providing a competitive advantage in the rapidly evolving diagnostic landscape. With a focus on innovation and customer-oriented solutions, Bioneer continues to solidify its role as a leading player in addressing influenza diagnostic needs in South Korea.

### **Key Companies in the South Korea Influenza Diagnostics Market Include**

- [bioMérieux](https://www.biomerieux.com/us/en/blog/diagnostic-digest/influenza.html)
- Bioneer
- GSK
- SanguiBiotech
- Abbott
- Merck
- SD Biosensor
- LabGenomics
- Roche
- Thermo Fisher Scientific
- MacoPharma
- Ortho Clinical Diagnostics
- Hologic
- Seegene
- Cepheid

## **South Korea Influenza Diagnostics****Market****Developments**

In recent months, the South Korea Influenza Diagnostics Market has witnessed significant developments, particularly in technological advancements and product launches.

Companies like bioMérieux, Abbott, and Roche have been focusing on enhancing their diagnostics capabilities with rapid tests and molecular diagnostics solutions, catering to the growing demand for efficient Influenza detection amid seasonal outbreaks.

In September 2023, a noteworthy acquisition occurred when Seegene acquired a subsidiary of LabGenomics, strengthening its position in the Influenza testing segment. Additionally, SD Biosensor has expanded its market reach with new partnerships aimed at improving accessibility to their diagnostic kits nationwide.

The growing emphasis on accurate and timely diagnosis is also driven by the increased funding from the South Korean government towards healthcare initiatives, along with the rise in demand for influenza diagnostic kits following the COVID-19 pandemic.

Major players like Merck, Hologic, and Thermo Fisher Scientific are investing in Research and Development to enhance their product offerings, ensuring a competitive edge in the market. Over the past few years, the market has experienced a surge in valuation attributed to these innovations and collaborations, reflecting the critical need for robust influenza diagnostic solutions in South Korea.

## **South Korea Influenza Diagnostics Market Segmentation Insights**

### **Influenza Diagnostics Market Type****Outlook**

- PCR Tests
- Antigen Tests
- Serology Tests
- Viral Culture
- Rapid Diagnostic Tests

### **Influenza Diagnostics Market Product****Outlook**

- Reagents
- Kits
- Instruments
- Consumables

### **Influenza Diagnostics Market****End-use****r****Outlook**

- Hospitals
- Clinics
- Laboratories
- Home Care

### **Influenza Diagnostics Market Technique****Outlook**

- Molecular Diagnostics
- Immunodiagnostics
- Cell Culture

## Market Drivers

### Government Funding and Support

Government funding and support play a crucial role in the growth of the influenza diagnostics market. In South Korea, the government has allocated substantial resources to enhance public health infrastructure, particularly in response to infectious diseases. Recent initiatives have included financial support for research and development of diagnostic technologies, which has led to innovations in rapid testing methods. The Ministry of Health and Welfare has reported an increase in budget allocations for influenza surveillance and diagnostics, with funding rising by 20% over the past two years. This financial backing encourages the development of new diagnostic tools and technologies, thereby expanding the market. As a result, the influenza diagnostics market is likely to experience significant growth driven by enhanced government initiatives aimed at improving public health outcomes.

### Rising Incidence of Influenza Cases

The increasing incidence of influenza cases in South Korea is a primary driver for the influenza diagnostics market. Seasonal outbreaks and sporadic epidemics contribute to heightened awareness among healthcare providers and the public. According to the Korea Centers for Disease Control and Prevention, influenza activity has shown a notable rise, with hospitalization rates increasing by approximately 15% in recent years. This trend necessitates the implementation of effective diagnostic tools to ensure timely identification and management of influenza infections. Consequently, healthcare facilities are investing in advanced diagnostic technologies, which is likely to bolster the influenza diagnostics market. The demand for rapid and accurate testing solutions is expected to grow, as early diagnosis is crucial for effective treatment and containment of the virus.

### Growing Awareness of Preventive Healthcare

There is a growing awareness of preventive healthcare among the South Korean population, which significantly impacts the influenza diagnostics market. As individuals become more health-conscious, there is an increasing demand for diagnostic tests that can identify influenza early. Public health campaigns and educational programs have emphasized the importance of early detection and vaccination, leading to a rise in testing rates. Recent surveys indicate that approximately 60% of the population is now more proactive about seeking diagnostic tests for influenza. This shift in consumer behavior is likely to drive the demand for innovative diagnostic solutions, as individuals seek to mitigate the risks associated with influenza infections. Consequently, the influenza diagnostics market is poised for growth as healthcare providers respond to this heightened demand for preventive measures.

### Technological Innovations in Diagnostic Tools

Technological innovations in diagnostic tools are transforming the landscape of the influenza diagnostics market. Advances in molecular diagnostics, such as polymerase chain reaction (PCR) and next-generation sequencing, have significantly improved the accuracy and speed of influenza testing. In South Korea, the adoption of these technologies has increased, with a reported growth of 25% in the use of molecular tests over the past year. These innovations not only enhance the reliability of test results but also facilitate the rapid identification of influenza strains, which is essential for effective treatment and public health response. As healthcare providers increasingly adopt these advanced diagnostic tools, the influenza diagnostics market is likely to expand, driven by the demand for more efficient and precise testing methods.

### Impact of Seasonal Variability on Testing Demand

Seasonal variability has a profound impact on the demand for influenza diagnostics in South Korea. The influenza season typically peaks during the winter months, leading to a surge in testing as healthcare providers aim to manage outbreaks effectively. Data from the Korea Centers for Disease Control and Prevention indicates that testing rates can increase by up to 30% during peak influenza seasons. This seasonal fluctuation creates a dynamic market environment, where diagnostic manufacturers must be prepared to meet the heightened demand during these critical periods. As healthcare systems adapt to these seasonal patterns, the influenza diagnostics market is likely to experience fluctuations in demand, necessitating strategic planning and resource allocation to ensure adequate testing capabilities throughout the year.

## Future Outlook

The [Influenza Diagnostics Market](https://www.marketresearchfuture.com/reports/influenza-diagnostics-market-3142) is projected to grow at an 8.29% CAGR from 2025 to 2035, driven by technological advancements, increased awareness, and rising healthcare expenditures.

**New opportunities:**

- Development of rapid point-of-care testing devices
- Integration of AI for predictive analytics in diagnostics
- Expansion of telehealth services for remote diagnostics

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Type: PCR Tests (Largest) vs. Antigen Tests (Fastest-Growing)

In the South Korea influenza diagnostics market, PCR tests hold the largest market share due to their high accuracy and reliability in detecting influenza viruses. These tests have been the gold standard and are widely implemented in clinical settings. Antigen tests follow as a significant segment, initially rising in popularity for their rapid results, which appeal to both healthcare providers and patients seeking quick diagnostics.

The growth trends indicate a strong push towards antigen tests as the fastest-growing segment in the market, driven by a demand for quicker turnaround times, particularly during flu seasons. Meanwhile, PCR tests continue to be favored for their precision and are expected to maintain substantial volume despite the competitive rise of other testing methods. Continued innovations and the shift towards at-home testing are likely to influence these segments further.

PCR Tests (Dominant) vs. Viral Culture (Emerging)

PCR tests are recognized as the dominant force in diagnostic testing for influenza, primarily due to their unmatched sensitivity and specificity. This dominance is supported by the availability of advanced PCR technologies that enhance testing efficiency. On the other hand, viral culture serves as an emerging technique, valued for its ability to isolate and characterize the virus, which is crucial for research and understanding influenza mutations. However, its longer turnaround time limits its use in clinical diagnostics compared to the rapid results offered by PCR. As public health initiatives focus on timely responses to outbreaks, PCR tests will likely remain the preferred method while viral culture gains traction in specialized laboratory settings.

### By Product: Kits (Largest) vs. Reagents (Fastest-Growing)

The South Korea influenza diagnostics market showcases a diverse distribution among its product segments, with kits leading the charge as the largest segment. Kits dominate this space due to their convenience, ease of use, and the increasing demand for rapid diagnosis in clinical settings. In contrast, reagents are gaining traction, representing a significant emerging segment within the market, driven by technological advancements and a growing emphasis on the accuracy and efficiency of diagnostic tests.

Over recent years, the market has seen a notable shift towards automation and the adoption of advanced technologies, which propels the growth of reagents as the fastest-growing product segment. This growth is fueled by the increasing investments in research and development and the rising incidence of influenza, which drives the demand for effective diagnostic solutions. The integration of digital health technologies is also enhancing the speed of diagnosis and treatment, further benefiting the reagents segment.

Kits (Dominant) vs. Reagents (Emerging)

Kits are undoubtedly the dominant force in the South Korea influenza diagnostics market, favored for their comprehensive solutions that combine ease of use with reliability. They cater to healthcare professionals seeking quick and accurate testing results, which is crucial in managing influenza outbreaks. On the other hand, reagents are emerging as a vital segment due to their role in enhancing the precision of diagnostic assays. As healthcare providers prioritize accuracy, reagents are becoming increasingly popular, particularly with the rise of point-of-care testing. This segment benefits from innovations that streamline testing processes while providing robust performance, attracting attention from both healthcare facilities and diagnostics manufacturers in a rapidly evolving market.

### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the South Korea influenza diagnostics market, hospitals hold the largest share among end users, benefiting from their comprehensive diagnostic capabilities and advanced healthcare infrastructure. Clinics, while smaller in market share, are emerging rapidly in popularity due to the increasing preference for primary healthcare settings for swift diagnostic services.

Growth trends indicate a positive trajectory for both hospitals and clinics in this segment. Hospitals continue to invest in cutting-edge diagnostic technologies, enhancing capabilities, and ensuring accurate results. Conversely, clinics are seeing growth driven by the rise in home healthcare and the need for accessible diagnostic services, suggesting a shift in patient behavior toward convenience and immediate care.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals represent the dominant force within the South Korea influenza diagnostics market, equipped with state-of-the-art technology and skilled personnel to manage a wide range of diagnostic tests. Their large-scale operations allow for substantial testing capacities, essential during peak influenza seasons. On the other hand, clinics are emerging as a significant segment, capitalizing on the demand for prompt and localized diagnostic services. The convenience offered by clinics, often located within community reach, positions them well for growth, particularly as patients seek quicker and more accessible options for their healthcare needs. As healthcare dynamics evolve, both segments are likely to play critical roles in shaping the future of influenza diagnostics.

### By Technique: Molecular Diagnostics (Largest) vs. Immunodiagnostics (Fastest-Growing)

In the South Korea influenza diagnostics market, Molecular Diagnostics holds the largest market share due to its rapid and accurate detection capabilities. This technique is preferred in clinical laboratories for its sensitivity and specificity, enabling timely intervention in influenza outbreaks. Immunodiagnostics, while smaller in overall share, is rapidly gaining traction among healthcare providers for its practicality and cost-effectiveness. 

The growth trends in this segment are primarily driven by the increasing prevalence of influenza viruses and a growing emphasis on early diagnosis and treatment. Furthermore, advancements in technology and the integration of automated systems in laboratories are enhancing the adoption of both Molecular and Immunodiagnostics. This is complemented by government initiatives to improve healthcare infrastructure, making innovative diagnostic methods more accessible.

Molecular Diagnostics (Dominant) vs. Immunodiagnostics (Emerging)

Molecular Diagnostics stands out as the dominant technique in the South Korea influenza diagnostics market, characterized by its molecular testing capabilities that offer unmatched accuracy and speed in detecting viral RNA. Its robust performance in clinical settings allows for rapid pandemic responses, positioning it at the forefront of diagnostic innovation. In contrast, Immunodiagnostics is emerging as a viable alternative, leveraging antibody detection methods that provide valuable insights into patient immunity and infection status. While it currently holds a smaller market share, its growth is fueled by increased demand for point-of-care testing and the development of user-friendly kits. The duality of these techniques caters to diverse needs within the healthcare system.

## Competitive Benchmarking

The [influenza diagnostics](https://www.marketresearchfuture.com/reports/influenza-diagnostics-market-3142) market in South Korea is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Roche (CH), Abbott (US), and Thermo Fisher Scientific (US) are actively pursuing strategies that emphasize technological advancements and enhanced diagnostic capabilities. Roche (CH) focuses on integrating digital solutions into its diagnostic platforms, which not only improves accuracy but also streamlines the testing process. Abbott (US), on the other hand, is leveraging its extensive distribution network to enhance accessibility to its rapid testing solutions, thereby positioning itself as a leader in point-of-care diagnostics. Meanwhile, Thermo Fisher Scientific (US) is concentrating on expanding its product portfolio through strategic acquisitions, which allows it to offer a more comprehensive suite of diagnostic tools.
The business tactics employed by these companies reflect a market structure that is moderately fragmented, with a mix of established players and emerging innovators. Localizing manufacturing and optimizing supply chains are critical strategies that these companies adopt to enhance operational efficiency and reduce costs. This collective approach not only strengthens their market presence but also fosters a competitive environment where agility and responsiveness to market demands are paramount.
In October 2025, Roche (CH) announced the launch of a new digital platform designed to enhance the integration of its influenza diagnostic tests with electronic health records. This strategic move is significant as it aims to improve data management and patient outcomes, thereby reinforcing Roche's commitment to innovation in diagnostics. The platform is expected to facilitate real-time data sharing among healthcare providers, which could lead to more timely interventions and better management of influenza outbreaks.
In September 2025, Abbott (US) expanded its collaboration with local healthcare providers in South Korea to enhance the distribution of its rapid influenza tests. This initiative is crucial as it not only increases the availability of Abbott's products but also strengthens its foothold in the region. By working closely with local entities, Abbott is likely to gain valuable insights into market needs, which can inform future product development and marketing strategies.
In August 2025, Thermo Fisher Scientific (US) completed the acquisition of a South Korean biotech firm specializing in molecular diagnostics. This acquisition is pivotal as it allows Thermo Fisher to enhance its technological capabilities and expand its product offerings in the influenza diagnostics space. The integration of advanced molecular techniques is expected to improve the accuracy and speed of influenza testing, thereby addressing a critical need in the market.
As of November 2025, the competitive trends in the influenza diagnostics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological innovation, reliability of supply chains, and the ability to deliver rapid, accurate diagnostics. This shift suggests that companies that prioritize these aspects may gain a competitive edge in the increasingly dynamic market.

## Recent News & Developments

In recent months, the South Korea Influenza Diagnostics Market has witnessed significant developments, particularly in technological advancements and product launches.

Companies like bioMérieux, Abbott, and Roche have been focusing on enhancing their diagnostics capabilities with rapid tests and molecular diagnostics solutions, catering to the growing demand for efficient Influenza detection amid seasonal outbreaks.

In September 2023, a noteworthy acquisition occurred when Seegene acquired a subsidiary of LabGenomics, strengthening its position in the Influenza testing segment. Additionally, SD Biosensor has expanded its market reach with new partnerships aimed at improving accessibility to their diagnostic kits nationwide.

The growing emphasis on accurate and timely diagnosis is also driven by the increased funding from the South Korean government towards healthcare initiatives, along with the rise in demand for influenza diagnostic kits following the COVID-19 pandemic.

Major players like Merck, Hologic, and Thermo Fisher Scientific are investing in Research and Development to enhance their product offerings, ensuring a competitive edge in the market. Over the past few years, the market has experienced a surge in valuation attributed to these innovations and collaborations, reflecting the critical need for robust influenza diagnostic solutions in South Korea.

## Report Scope

| MARKET SIZE 2024 | 185.28(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 200.64(USD Million) |
| MARKET SIZE 2035 | 444.87(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.29% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (CH), Abbott (US), Thermo Fisher Scientific (US), Siemens Healthineers (DE), BD (US), Cepheid (US), QuidelOrtho (US), Hologic (US) |
| Segments Covered | Type, Product, End User, Technique |
| Key Market Opportunities | Integration of rapid testing technologies enhances influenza diagnostics market responsiveness and accuracy. |
| Key Market Dynamics | Rising demand for rapid influenza diagnostics drives innovation and competition among local manufacturers in South Korea. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What was the overall market valuation of the influenza diagnostics market in 2024?**
A: The overall market valuation was $185.28 Million in 2024.

**Q: What is the projected market valuation for the influenza diagnostics market by 2035?**
A: The projected market valuation for 2035 is $444.87 Million.

**Q: What is the expected CAGR for the influenza diagnostics market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 8.29%.

**Q: Which companies are considered key players in the influenza diagnostics market?**
A: Key players include Roche (CH), Abbott (US), Thermo Fisher Scientific (US), Siemens Healthineers (DE), BD (US), Cepheid (US), QuidelOrtho (US), and Hologic (US).

**Q: What were the revenue figures for PCR tests in 2024?**
A: In 2024, the revenue for PCR tests was $37.06 Million.

**Q: How much is the market for antigen tests projected to grow by 2035?**
A: The market for antigen tests is projected to grow to $130.0 Million by 2035.

**Q: What is the revenue forecast for serology tests in 2035?**
A: The revenue forecast for serology tests in 2035 is $43.0 Million.

**Q: What segment generated the highest revenue in 2024?**
A: The segment that generated the highest revenue in 2024 was antigen tests, with $55.92 Million.

**Q: What is the expected revenue for consumables in 2035?**
A: The expected revenue for consumables in 2035 is $164.87 Million.

**Q: Which end user segment is projected to have the highest revenue by 2035?**
A: The hospitals segment is projected to have the highest revenue by 2035, reaching $176.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-influenza-diagnostics-market-56865*